Author

Hideki Onishi

OpenAlex ID: A5148159158

Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study

2026 · Masatoshi Kudo, Masatoshi Kudo, et al. · The Lancet Oncology

Works count: 1

Citation count:

H-index:

I10-index: